Increased osteoclast activity, induced by osteoclast-derived osteopontin and vascular endothelial growth factor (VEGF) from myeloma cells, appears to contribute both to the increased angiogenesis and tumor growth in MM [18,21]. The gene discussed is SPP1; the disease is Miyoshi myopathy.